重组人尿激酶原静脉溶栓治疗STEMI的疗效和安全性研究

高宏波; 郭欣; 王永进; 卫娇娜; 丁钰轩; 杜亚坤; 白晓君; 赵宽; 黄新亮

doi:10.12125/j.chj.202107021

重组人尿激酶原静脉溶栓治疗STEMI的疗效和安全性研究

Efficacy and safety of thrombolytic therapy using recombinant prourokinase in patients with acute myocardial infarction with ST-segment elevation

摘要

摘要:
目的观察重组人尿激酶原(rhPro-UK) 经静脉溶栓治疗急性ST段抬高型心肌梗死(STEMI)的临床疗效和安全性。
方法选择汉中市人民医院静脉溶栓治疗的STEMI患者，根据患者溶栓药物不同分为重组人尿激酶原组(n=206)和尿激酶组(n=92)，收集两组患者的基线资料和冠状动脉造影资料，比较两组患者临床冠脉再通率、冠脉造影TIMI≥2级开通率、主要出血事件和其他并发症发生率。
结果与尿激酶组患者比较，重组人尿激酶原组临床再通率164(79.62 %) vs. 52(63.04 %), P<0.01和TIMI≥2级开通率149(82.78 %) vs. 50(65.79 %), P<0.01显著提高，且主要出血事件15(7.8 %) vs. 14(15.22 %), P<0.05和并发症发生率5(2.3 %) vs. 8(8.70%), P<0.05显著降低。
结论重组人尿激酶原静脉溶栓治疗 STEMI 患者血管再通率优于尿激酶，且出血事件及其他并发症发生率低。

Abstract:
AIM To observe the clinical efficacy and safety of thrombolytic therapy using recombinant prourokinase (rhPro-UK) in patients with acute myocardial infarction with ST-segment elvation (STEMI).
METHODS STEMI patients with thrombolysis were selected and were divided into recombinant prourokinase group (n=206) and urokinase group (n=92). Baseline data of the two groups were collected, and clinical coronary recanalization rate, coronary angiography TIMI≥2 opening rate, major bleeding events and complication rate were compared between the two groups.
RESULTS Compared with those in urokinase group, the clinical recanalization rate 164 (79.62%) vs. 52 (63.04%), P<0.01 and the opening rate of TIM≥2 149 (82.78%) vs. 50 (65.79%), P<0.01 were significantly improved in recombinant prourokinase group, while the major bleeding events 15 (7.8%) vs. 14(15.22%), P<0.05 and the complication rate 5 (2.3%) vs. 8 (8.70%), P<0.05 were significant reduced.
CONCLUSION Recombinant prourokinase has a higher rate of thrombolytic vascular recanalization and a lower incidence of bleeding events and complications.

HTML全文

参考文献(22)

施引文献

资源附件(0)